Latest Breaking News On - இரத்தம் கோளாறுகள் மையம் - Page 5 : comparemela.com

 E-Mail Higher percentage of patients treated with nivolumab and ipilimumab in clinical trial reach the six-and-a-half-year survival mark than those treated with either drug alone. BOSTON - In the longest follow-up results from a clinical trial of combination immunotherapy for metastatic melanoma, investigators report that nearly half the patients who received the drugs nivolumab and ipilimumab were alive a median of six and a half years after treatment. The results, stemming from the CheckMate 067 clinical trial, represent a new landmark in survival rates for patients with melanoma treated with immune checkpoint inhibitor drugs. F. Stephen Hodi, MD, the director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber Cancer Institute is co-senior author of the study. Findings will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually June 4-8.

United statesDana farber cancer instituteF stephen hodiDana farber brighamBlood disorders centerAmerican society of clinical oncologyMelanoma centerWomen cancer centerOncology at dana farber cancer instituteBristol myers squibbStephen hodiClinical oncologyAnnual meetingBristol myersSkin cancers oral abstract sessionVictoria warren